Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jason Ostergaard"'
Autor:
Xiaohong Wang, Jason Ostergaard, Jongseok Kang, Grace Sagong, Rachel Twite, Andrea Vargas-Morales, Peter M. Gordon
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with relapse being a major obstacle to successful treatment. Our understanding of the mechanisms driving chemotherapy resistance and ultimately relapse in leukemia remains in
Externí odkaz:
https://doaj.org/article/2657e6b122ed4037a226415b1a2c1bf7
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract Central nervous system (CNS) relapse is a significant cause of treatment failure among patients with acute lymphoblastic leukemia. In prior work we found that the meninges, the thin layer of tissue that covers the brain and spinal cord, harb
Externí odkaz:
https://doaj.org/article/2de1b920152043c28d8ada5d61e60d84
Autor:
Stacia L. Koppenhafer, Kelli L. Goss, Ellen Voigt, Emma Croushore, William W. Terry, Jason Ostergaard, Peter M. Gordon, David J. Gordon
Publikováno v:
Oncogene. 41:2873-2884
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f5093404c7a25cb27cb5d8a69e16713
https://doi.org/10.1038/s41388-022-02310-0
https://doi.org/10.1038/s41388-022-02310-0
Autor:
Leslie M. Jonart, Jason Ostergaard, Athena Brooks, Garrett Fitzpatrick, Liam Chen, Peter M. Gordon
Publikováno v:
Br J Haematol
The effective prophylaxis and treatment of central nervous system (CNS) involvement in acute lymphoblastic leukaemia (ALL) remains a significant clinical challenge. Developing novel and more effective CNS-directed therapies has been hampered, in part
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df390eef391e91cbb651044837bee62c
https://europepmc.org/articles/PMC10121760/
https://europepmc.org/articles/PMC10121760/
Autor:
Jason Ostergaard, David Gordon, Leslie M. Jonart, Stacia L. Koppenhafer, Peter M. Gordon, Maryam Ebadi
Publikováno v:
Br J Haematol
The addition of molecularly targeted therapies to current chemotherapy regimens may improve acute lymphoblastic leukemia (ALL) outcomes and reduce acute and late toxicities. Checkpoint kinase 1 (CHK1) orchestrates cell cycle checkpoint control in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28fcd63bb7441a7efd1bce74a64a19c9
https://doi.org/10.1111/bjh.17610
https://doi.org/10.1111/bjh.17610
Autor:
Peter M. Gordon, Jason Ostergaard, Leslie M. Jonart, M Frank Erasmus, Bridget S. Wilson, Stuart S. Winter
Publikováno v:
Blood. 140:9201-9202
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6733829e135e11bbf2957227968cefb3
https://doi.org/10.1182/blood-2022-159115
https://doi.org/10.1182/blood-2022-159115
Autor:
Stacia L, Koppenhafer, Kelli L, Goss, Ellen, Voigt, Emma, Croushore, William W, Terry, Jason, Ostergaard, Peter M, Gordon, David J, Gordon
Publikováno v:
Oncogene. 41(20)
Sarcomas are difficult to treat and the therapy, even when effective, is associated with long-term and life-threatening side effects. In addition, the treatment regimens for many sarcomas, including Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4c53429031f0deb25fa77afe93686ffd
https://pubmed.ncbi.nlm.nih.gov/35422476
https://pubmed.ncbi.nlm.nih.gov/35422476
Autor:
Michelle M. Frees, George Maxwell Otto, Sandra Wagner, David J. Odde, David A. Largaespada, Paramita Das, Pauline J. Beckmann, Rory L. Williams, Barbara R. Tschida, Robert B. Jenkins, Alex T. Larsson, Stephen C Schmechel, Quincy Rosemarie, Jon D. Larson, Charles G. Eberhart, Fausto J. Rodriguez, Eric P. Rahrmann, Xiaochong Wu, Jason Ostergaard, Jun Wang, Addison M. Demer, Michael D. Taylor, Daniel Picard, Adrian M. Dubuc, Ryan D Krebs, Catherine Lee, Annie Huang, Aaron L. Sarver, Robert J. Wechsler-Reya, Branden S. Moriarity, Anthony E. Rizzardi, Amy M. Molan, Ghaidan Shamsan
Publikováno v:
Cancer Research. 79:905-917
Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNET) are aggressive, poorly differentiated brain tumors with limited effective therapies. Using Sleeping Beauty (SB) transposon mutagenesis, we identified novel genetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a40f8f826ae2377aa0bdaea941a7d85f
https://doi.org/10.1158/0008-5472.can-18-1261
https://doi.org/10.1158/0008-5472.can-18-1261
Autor:
Kelli L. Goss, Peter M. Gordon, Kuo Kuang Wen, William W. Terry, Torin Waters, Jason Ostergaard, David Gordon, Meng Wu, Stacia L. Koppenhafer
Publikováno v:
Oncogene
Ribonucleotide reductase (RNR), which is a heterodimeric tetramer composed of RRM1 and RRM2 subunits, is the rate-limiting enzyme in the synthesis of deoxyribonucleoside triphosphates (dNTPs) and essential for both DNA replication and the repair of D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebe3fc3ee2ddc9aca2bc9f181ac25c3d
https://pubmed.ncbi.nlm.nih.gov/33191406
https://pubmed.ncbi.nlm.nih.gov/33191406
Publikováno v:
Neuro-Oncology. 20:vi51-vi51
Medulloblastoma and central nervous system primitive neuroectodermal tumors (CNS-PNETs) are aggressive, poorly differentiated brain tumors that primarily affect children. Current treatment strategies with severe long-term treatment-related side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31a0c9d39b1b73902336bf3bda1e6e15
https://doi.org/10.1093/neuonc/noy148.203
https://doi.org/10.1093/neuonc/noy148.203